RecruitingPhase 2NCT06651489

Efficacy of Guselkumab in Treating Hailey Hailey Disease

Studying Hailey-Hailey disease

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Yale University
Principal Investigator: Keith Choate, MD, PhD
Yale University
Intervention: Guselkumab(drug)
Enrollment: 10 target
Eligibility: 18-90 years · All sexes
Timeline: 2025 – 2026

Study locations (1)

Church Street Research Unit, Yale Center for Clinical Investigation, New Haven, Connecticut, United States

Collaborators

Janssen Scientific Affairs, LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06651489 on ClinicalTrials.gov

← Back to all trials